Biosimilars

biosimilars_promo.jpg

Sandoz has an unwavering commitment to increasing patient access to high-quality, life-enhancing biosimilars. Sandoz is the global market leader and currently markets three biosimilars outside the US, each of which occupies the #1 biosimilar position in its respective category. Sandoz has a leading pipeline with several biosimilars across the various stages of development, including five programs in Phase III clinical trials/filing preparation.

News

Sandoz licenses its biosimilar rituximab to Kyowa Hakko Kirin in Japan

January 25, 2016

Sandoz announced today that it has entered into an exclusive license agreement with Kyowa Hakko Kirin Co., Ltd for the distribution and promotion of its biosimilar rituximab.

...

Biosimilars: The Sandoz Way
Joerg Windisch talks about biosimilars development and manufacturing at Sandoz.

Watch the video

Biosimilar medicines offer physicians more choices at affordable prices thereby increasing patient access without increasing overall spending.

Read more

Bending the curve of rising healthcare costs without compromising access to quality medical care for its citizens remains one of the most daunting challenges that governments are faced with.

Read more